ISAB — Inhalation Sciences Sweden AB Income Statement
0.000.00%
Last trade - 00:00- SEK12.51m
- SEK8.51m
- SEK11.05m
Annual income statement for Inhalation Sciences Sweden AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.1 | 9.42 | 12.2 | 17.5 | 11 |
| Cost of Revenue | |||||
| Gross Profit | 6.76 | 5.22 | 9.64 | 14 | 10.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | -0.596 | 26 | 24.2 | 21.3 | 16.1 |
| Operating Profit | 10.7 | -16.6 | -12 | -3.76 | -5.08 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 9.88 | -16.6 | -12.1 | -4.74 | -5.15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 9.88 | -16.6 | -12.1 | -4.74 | -5.15 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 9.88 | -16.6 | -12.1 | -4.74 | -5.15 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 9.88 | -16.6 | -12.1 | -4.74 | -5.15 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.11 | -1.66 | -1.07 | -0.357 | -0.339 |
| Dividends per Share |